PLEASANTON, Calif., March 22, 2018 -- Co-founder and CEO of Title21 Health Solutions (www.Title21.com) Lynn Fischer will share her purpose-driven career story on The MENTORS RADIO SHOW this weekend. Listeners can hear the interview live on KTRB AM860 San Francisco at 7am PT on Saturday, March 24 and at noon on Sunday, March 25; and KCBQ AM1170 San Diego at 12pm PT Saturday, March 24; and on-demand anytime on TheMentorsRadio.com. Title21 Health Solutions is an innovative technology company in the San Francisco Bay Area that delivers integrated, easy-to-use Cloud Enterprise Quality Management Systems and end-to-end software that digitizes cell and gene manufacturing and bone marrow transplant programs.
Hosted by Mentor Tom Loarie, Ms. Fischer tells her story of pivoting a successful consumer packaged goods Marketing career with Gallo Winery, Dreyer’s Grand Ice Cream, M&M/Mars and The Wine Group to lead a patient-centric healthcare technology company. Lynn discusses how her passion to make a difference and improve patient quality and outcomes were the motivating factors to make the move to healthcare. “At the age of fifteen my Dad and mentor was diagnosed with melanoma, and Memorial Sloan Kettering Cancer Center saved his life. That experience had a profound impact on my desire to support the advancement of innovative, curative therapies through technology.”
Host, Tom Loarie stated, “Anyone considering a major career pivot will be inspired by Lynn’s story which reminds us that anything is possible when you allow your purpose and passion to steer your career journey.”
Ms. Fischer remarks, “I hope my career story will inspire others to lead with their heart and pursue a career that serves others even if it requires a pivot. Wine to healthcare technology was a big jump. If I can do it, anyone can.”
About Title21 Health Solutions
Title21 Health Solutions continues to gain national recognition for its innovative technology to help hospitals, biotechnology, regenerative medicine and other health science organizations improve quality, efficiency and patient safety. Title21’s product line includes web-based quality management solutions and the first end-to-end cell and gene therapy software available in the market. Learn more about Title21 and rewarding careers at www.Title21.com.
Media Contact Haley Roebuck [email protected]


Heineken H1 Operating Profit Meets Forecast as Beer Volumes Beat Expectations
Apple Restores Telegram to App Store After Content Policy Violation
DoorDash Q2 Revenue Jumps 36% as Orders and DashPass Growth Drive Results
Palantir Stock Soars as AI Demand Drives Strong Q2 Earnings and Higher 2026 Outlook
DHL Q2 Profit Jumps 24% as Express Business Drives Growth
Novo Nordisk Raises 2025 Outlook Despite Wegovy Pill Miss and CagriSema Setback
Infineon Raises 2026 Revenue Outlook as AI Data Center Demand Fuels Record Quarterly Sales
Trump Urges Exxon, Chevron to Cut Gas Prices After Record Oil Profits
Glencore Posts Strong H1 2026 Earnings, Announces ASX Secondary Listing
Alphabet Stock Slides as Google AI Pioneer Jeff Dean Exits to Launch Discovery Loop
Meta AI Model Exploits Security Flaw During Cybersecurity Test, Raising AI Safety Concerns
Jetstar to Charge for Overhead Cabin Bags From February
HSBC H1 Profit Jumps 23%, Announces $1 Billion Share Buyback and Reaffirms 2028 Targets
Samsung, SK Hynix Test AMEC Chipmaking Tools for China Backup Plan
Siemens Energy Q3 Profit Beats Forecast as AI-Driven Power Demand Fuels Growth
Western Digital Q4 Earnings Beat Estimates as FY2027 Outlook Tops Expectations
Novo Nordisk Eyes Turnaround as Oral Wegovy Challenges Eli Lilly in Weight-Loss Drug Race 



